TY - JOUR
T1 - A prospective, randomized trial to assess the cost impact of pharmacist- initiated interventions
AU - McMullin, S. Troy
AU - Hennenfent, Joel A.
AU - Ritchie, David J.
AU - Huey, Way Y.
AU - Lonergan, Thomas P.
AU - Schaiff, Robyn A.
AU - Tonn, Michael E.
AU - Bailey, Thomas C.
PY - 1999/10/25
Y1 - 1999/10/25
N2 - Background: Hospital pharmacists make many recommendations that improve patients' quality of care and/or reduce drug costs. While the impact of quality-of-care interventions is difficult to quantify, those limited to cost savings could be assessed in a prospective, randomized fashion. Objective: To assess the impact of pharmacist-initiated interventions on cost savings. Methods: Six pharmacists at a large university hospital recorded patient- specific recommendations for 30 days. All quality-of-care interventions were completed by the pharmacists, but those strictly aimed at reducing costs were stratified by drug class and randomized to an intervention or control group. Pharmacists contacted physicians with cost-saving recommendations in the intervention group, while control group patients were simply observed. Main Outcome Measure: Drug costs after randomization. Results: Most (n=967 [79%]) of the 1226 interventions recorded were aimed at improving quality of care. The remaining 259 (21%) provided equivalent quality of care, but at less expense. These cost-saving interventions typically involved streamlining therapy to less expensive agents (39%), discontinuing an unnecessary medication (25%), or modifying the route of administration (24%). The group randomized to receive a pharmacist's intervention had drug costs that were 41% lower than those in the control group (mean, $73.75 vs $43.40; P<.001). Interventions involving anti-infective agents had the greatest cost savings (mean, $104.08 vs $58.45; P<.001). For our institution, this extrapolates to an annual savings of approximately $394 000 (95% confidence interval, $46 000-$742 000). As expected, these interventions had no impact on length of hospital stay, inhospital mortality, 30-day readmissions, or the need to readminister the targeted medication or restart intravenous therapy. Conclusions: While interventions solely aimed at reducing costs represent a small portion of a pharmacist's activities, they can result in significant savings for an institution.
AB - Background: Hospital pharmacists make many recommendations that improve patients' quality of care and/or reduce drug costs. While the impact of quality-of-care interventions is difficult to quantify, those limited to cost savings could be assessed in a prospective, randomized fashion. Objective: To assess the impact of pharmacist-initiated interventions on cost savings. Methods: Six pharmacists at a large university hospital recorded patient- specific recommendations for 30 days. All quality-of-care interventions were completed by the pharmacists, but those strictly aimed at reducing costs were stratified by drug class and randomized to an intervention or control group. Pharmacists contacted physicians with cost-saving recommendations in the intervention group, while control group patients were simply observed. Main Outcome Measure: Drug costs after randomization. Results: Most (n=967 [79%]) of the 1226 interventions recorded were aimed at improving quality of care. The remaining 259 (21%) provided equivalent quality of care, but at less expense. These cost-saving interventions typically involved streamlining therapy to less expensive agents (39%), discontinuing an unnecessary medication (25%), or modifying the route of administration (24%). The group randomized to receive a pharmacist's intervention had drug costs that were 41% lower than those in the control group (mean, $73.75 vs $43.40; P<.001). Interventions involving anti-infective agents had the greatest cost savings (mean, $104.08 vs $58.45; P<.001). For our institution, this extrapolates to an annual savings of approximately $394 000 (95% confidence interval, $46 000-$742 000). As expected, these interventions had no impact on length of hospital stay, inhospital mortality, 30-day readmissions, or the need to readminister the targeted medication or restart intravenous therapy. Conclusions: While interventions solely aimed at reducing costs represent a small portion of a pharmacist's activities, they can result in significant savings for an institution.
UR - http://www.scopus.com/inward/record.url?scp=0032736868&partnerID=8YFLogxK
U2 - 10.1001/archinte.159.19.2306
DO - 10.1001/archinte.159.19.2306
M3 - Article
C2 - 10547170
AN - SCOPUS:0032736868
SN - 0003-9926
VL - 159
SP - 2306
EP - 2309
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
IS - 19
ER -